HighGravityDataBioMarin Pharmaceutical — Feb 19, 2025 release
Fiscal 2024 fourth-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001048477-25-000004
Showing in the filing
VOXZOGO contribution to full-year 2025 Total Revenues
“$900 million to $950 million”
Period
FY2025
Measure
GAAP-tied
Source
Prose
All guidance in this release · 14
Revenue and profitability growth for FY2025
“Double-Digit”
VOXZOGO country availability for FY2027
“more than 60 countries”
VOXZOGO Revenue CAGR for FY2023
“exceeding 25%”
Enzyme Therapies long-term growth outlook (C… for the long term
“high single-digit CAGR”
Cost transformation program size for FY2024
“$500 million”
Non-GAAP Operating Margin for FY2026
“40%”
Total Revenues for FY2027
“approximately $4 billion”
Non-GAAP Operating Margin growth for FY2025
“14% (3.9 percentage points) Y/Y at the mid-point of guidance”
Operating cash flows for FY2027
“more than $1.25 billion”
Total Revenues for FY2025
“$3,100 to $3,200”
Non-GAAP Operating Margin % for FY2025
“32% to 33%”
Non-GAAP Diluted EPS for FY2025
“$4.20 to $4.40”
VOXZOGO contribution to full-year 2025 Total… for FY2025
“$900 million to $950 million”
Weighted-Average Diluted Shares Outstanding … for FY2025
“approximately 200 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
2025 Full-Year Financial Guidance (in millions, except % and EPS amounts) Item 2025 Guidance Total Revenues (1) $3,100 to $3,200 Non-GAAP Operating Margin % (2) 32% to 33% Non-GAAP Diluted EPS (2)(3) $4.20 to $4.40 (1) VOXZOGO contribution to full-year 2025 Total Revenues expected to be in the range of $900 million to $950 million. (2) Refer to Non-GAAP Information beginning on page 10 of this press release for definitions of Non-GAAP Operating Margin and Non-GAAP Diluted EPS. (3) Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted-Average Diluted Shares Outstanding. BioMarin will host a conference call and webcast to discuss fourth quarter and full-year 2024 financial results today, Wednesday, February 19, 2025, at 4:30 p.m. ET. This event can be accessed through this link or on the investor section of the BioMarin website at www.biomarin.com. U.S./Canada Dial-in Number: 800-715-9871 Replay Dial-in Number: 800-770-2030 International Dial-in Number: 646-307-1963 Replay International Dial-in Number: 609-800-9909 Conference ID: 1878833 Conference ID: 1878833 About BioMarin BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, B
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.